Clinical trials: Cardio-Renal Syndrome
Chronic Kidney Diseases, Chronic Heart Failure
The Impact of CRT on Renal Function
The study is observational, prospective, including patients undergoing CRT-D / CRT-P implantation in the department of cardiology.
- Trial name
- NCT04516525
- Testing
- cardiac resynchronisation therapy (CRT) implantation
- Volunteers
- 74 people
- Sponsor
- University of Rzeszow
Hypertension
Valsartan in Cardiovascular Disease With Renal Dysfunction (The V-CARD) Study
The purpose of this study is to investigate if an angiotensin II receptor blocker, valsartan 160 mg/day is more effective to reduce the incidence of cardiovascular events as compared to 40 mg/day in patients with moderate renal…
- Trial name
- NCT00140790
- Testing
- valsartan
- Where
- 2 sites in Japan
- Volunteers
- 1,000 people
- Sponsor
- Kumamoto University
Cardio-Renal Syndrome
Bioimpedance and Hand-held Echocardiographay for Clinical Decision-making in Treatment of Cardio-renal Syndrome Type I
The purpose of this study is to investigate whether hemodynamic data obtained by a noninvasive bio-impedance system (NICAS) sampled from patients with cardiorenal syndrome type I (CRS1) improve clinical outcomes.
- Trial name
- NCT02959281
- Testing
- Providing caring physicians with hemodynamic variables
- Sponsor
- HaEmek Medical Center, Israel
Heart Failure, Kidney Diseases
Research on Optimal Diagnosis and Treatment of Cardiorenal Syndrome
To estimate the characteristics, pathogenesis, risk factors and intervention measures for different stages of heart and kidney diseases, and to optimize the curative effects of different treatment schemes
- Conditions
- Heart Failure, Kidney Diseases, Kidney Injury, Heart Valve Diseases
- Trial name
- ODT-CRS (NCT05397392)
- Testing
- guideline recommended routine treatment
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Acute Decompensated Heart Failure
Assessment of Biomarkers and Cardiorenal Syndrome in Acute Decompensated Heart Failure With Vasodilator Therapy
The purpose of this study is to determine whether Nesiritide is more effective than nitroglycerin in modifying inflammatory and neurohormonal biomarkers without renal toxicity when proper infusion duration is administered.
- Trial name
- ABC-HFT (NCT00842023)
- Testing
- Nesiritide, Nitroglycerin
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Western University of Health Sciences
Glycocalyx, Cardio-Renal Syndrome
Damage and Renal Clearance of Glycocalyx in Cardiac Surgery
The glycocalyx is a component of the vascular endothelium that currently plays a relevant role in the modified Starling theory. The manipulation of the heart during cardiac surgery stimulates the release of the natriuretic atrial…
- Trial name
- GlycoCarSur (NCT04332952)
- Where
- Mexico
- Volunteers
- 21 people
- Sponsor
- Miguel Ayala León
Acute on Chronic Systolic Congestive Heart Failure, Cardiorenal Syndrome
Feasibility of the SCD in Cardiorenal Syndrome Patients Awaiting LVAD
Cardiovascular disease is the leading cause of mortality in the US, accounting for 45% of all deaths. Chronic Heart Failure (CHF) is now understood to be a multi-system disease process involving not only the cardiovascular system…
- Trial name
- NEUTRALIZE-CRS (NCT03836482)
- Testing
- Selective Cytopheretic Device
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- SeaStar Medical
Cardiorenal Syndrome
Accuracy of Urinary NGAL in Predicting CardioRenal Syndrome in Acute Heart Failure at Emergency - CYNDERELA-HF Study
Rationale: Heart Failure (HF) elevated prevalence in Brasil and the world; 20-30% AHF patients develop CardioRenal Syndrome (CRS) type 1; Worsening Renal Failure (WRF) is a prognostic marker of mortality in Acute HF;NGAL is a…
- Trial name
- CYNDERELA-HF (NCT01364636)
- Where
- Brazil
- Volunteers
- 180 people
- Sponsor
- Pro-Cardiaco Hospital
Type 2 Diabetes Mellitus, Cardiovascular-Kidney-Metabolic Syndrome
Clinical Predictors and Therapeutic Gaps in CKM Syndrome Among Adults With Type 2 Diabetes
Type 2 diabetes (T2D) is a principal driver of cardiovascular-renal-metabolic (CKM) syndrome, where metabolic, renal, and cardiac dysfunction accelerate disease progression.
- Conditions
- Type 2 Diabetes Mellitus, Cardiovascular-Kidney-Metabolic Syndrome, Diabetic Kidney Disease
- Trial name
- CKM-T2D (NCT07854990)
- Testing
- clinical and laboratory CKM staging evaluation
- Where
- Egypt
- Volunteers
- 231 people
- Sponsor
- Assiut University
Tricuspid Regurgitation, Tricuspid Valve Insufficiency
Evaluation of the Impact of Interventional Treatments for Symptomatic, Severe Tricuspid Valve Insufficiency on Renal Integrity and Function, as Well as on Physical Function and Activity in Older Adults.
The hypothesis is that renal function will improve following tricuspid valve intervention. A reduction in renal biomarkers is also expected.
- Conditions
- Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Cardio-Renal Syndrome, Frailty
- Trial name
- TriRenGe (NCT07464106)
- Testing
- Transcatheter edge-to-edge repair (TEER)
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- Robert Bosch Medical Center
C.Surgical Procedure; Cardiac, Acute Kidney Injury
Portal Flow Pulsatility as a Risk Factor for Acute Kidney Injury After Cardiac Surgery
The purpose of this study is to evaluate the possible association between portal vein flow pulsatility and acute kidney injury after cardiac surgery.
- Conditions
- C.Surgical Procedure; Cardiac, Acute Kidney Injury, Postoperative Complications, Right-Sided Heart Failure
- Trial name
- PP-AKI (NCT02831907)
- Testing
- Cardiac surgery
- Where
- Canada
- Volunteers
- 146 people
- Sponsor
- Montreal Heart Institute
Heart Failure Acute, Heart Failure; With Decompensation
Diuretic and Natriuretic Effect of High-dose Spironolactone in Patients With Acute Heart Failure
This is a prospective, single-center, open-label and randomized trial for evaluation of the effect of a 5-day administration of high doses of spironolactone (≥100mg daily) on diuresis, natriuresis, weight loss and levels of…
- Trial name
- DANAUS-AHF (NCT04618601)
- Testing
- Spironolactone
- Where
- Greece
- Volunteers
- 50 people
- Sponsor
- Laikο General Hospital, Athens
Morbid Obesity, Chronic Kidney Disease (Stage 3-4)
Metabolic Status and Risk of Chronic Kidney Disease in French Overseas Populations With Morbid Obesity (OBECAMcohort).
Morbid obesity is defined by a body mass index (BMI) ≥ 40 kg/m2 or > 35 if there is at least one comorbidity (hypertension, diabetes, hypercholesterolemia, joint pain, obstructive sleep apnea syndrome, etc.) Morbid obesity…
- Trial name
- OBECAMcohort (NCT07830030)
- Where
- Guadeloupe
- Volunteers
- 480 people
- Sponsor
- Clinique
Chronic Kidney Disease, Acute Heart Failure
Utility of Brain Natriuretic Peptide (BNP) in Patients With Type IV Cardio-renal Syndrome Admitted to the Intensive Care Unit (ICU)
Admission BNP was a useful marker for diagnosing and predicting type IV cardio-renal syndrome type IV in patients with chronic kidney disease admitted to the ICU for acute heart failure in a retrospective study.
- Trial name
- NCT01211886
- Volunteers
- 83 people
- Sponsor
- Hallym University Medical Center
Cardiorenal Syndrome
Exercise Rehabilitation for Cardiorenal Syndrome in HFrEF Patients
This study aims to investigate the efficacy and safety of exercise rehabilitation in patients with cardiorenal syndrome (CRS). Building on previous research demonstrating that exercise rehabilitation can effectively improve…
- Trial name
- NCT07167368
- Testing
- Standardized Basic Drug Therapy for HFrEF with Chronic Kidney Dysfunction, Home-based Personalized Exercise Rehabilitation
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Haiyan Pan
Chronic Kidney Disease, Type 2 Diabetes
RAndomized EHR-based Prescribing to Improve Disease-modifying Therapies for Cardio-Kidney-Metabolic Care (RAPID-CKM)
The goal of this pragmatic randomized clinical trial is to determine whether an Epic-based clinician notification increases initiation of guideline-directed cardio-kidney-metabolic (CKM) therapies in adults with type 2 diabetes…
- Trial name
- NCT07605390
- Testing
- Epic-Based Clinician Notification, Usual Care
- Where
- 2 sites in United States
- Volunteers
- 600 people
- Sponsor
- Baylor Research Institute
Ultrafiltration Failure
A Feasibility Study of Peritoneal Ultrafiltration With a Wearable Device, CLS UF, That Adds a Glucose-salt Solution to the Intraperitoneal Fluid in the Device, in Order to Maintain a Stable Intraperitoneal Osmolarity and Thereby Enhance Ultrafiltration.
The study is a proof-of-concept, a feasibility study of peritoneal ultrafiltration with a wearable device, Carry Life System Ultrafiltration (CLS UF) and will be performed on 4-6 stable peritoneal dialysis (PD) patients without…
- Trial name
- NCT03128073
- Testing
- Carry life system, ultrafiltration (CLS UF)
- Where
- Sweden
- Volunteers
- 5 people
- Sponsor
- Triomed AB
Congestive Heart Failure Exacerbation, Renal Insufficiency
BNP for Cardio-Renal Decompensation Syndrome (BNP-CARDS)
Many patients with exacerbations of heart failure have significant concomitant kidney dysfunction. The combination of these two conditions makes pharmacological management difficult.
- Trial name
- NCT00186329
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Stanford University
Empagliflozin in Cardiorenal Syndrome Type 1
The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1
Effects of Empagliflozin compared with placebo in cardiorenal syndrome type 1, evaluated by MAKE30.
- Trial name
- TREAT-CRS (NCT06030843)
- Testing
- Empagliflozin 10 MG
- Where
- Thailand
- Volunteers
- 200 people
- Sponsor
- Chulalongkorn University
Acute Kidney Injury, Kidney Failure Chronic
French AKI Registry (FAKIR): A Multicenter Study on the In-Hospital Management and Outcomes of Severe Acute Kidney Injury in Nephrology Units
Acute Kidney Injury (AKI) is a common and serious condition in hospitalized patients, especially when it reaches stages 2 or 3 according to the KDIGO classification.
- Conditions
- Acute Kidney Injury, Kidney Failure Chronic, Cardiorenal Syndrome, Renal Replacement Therapies
- Trial name
- FAKIR (NCT07123324)
- Volunteers
- 750 people
- Sponsor
- University Hospital, Strasbourg, France